The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | Structural variants in multiple myeloma: impact on outcomes & potential drug targets
Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York, NY, discusses the occurrence of structural variants in multiple myeloma, commenting on the impact of chromoplexy and chromothripsis on patient outcomes, and highlighting the possibility of finding new drivers that can be used as targets for therapy. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
